Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.

Trending

Deka Biosciences Raises $20 Million in Series A Financing

November 16, 2021
Maryland-based biotech company Deka Biosciences ("Deka") today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led... Learn More

Antiva Biosciences Closes $31 Million Series D Equity Financing

November 5, 2021
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today... Learn More

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

November 3, 2021
Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful... Learn More

LAVA Medtech Acquisition Corp. Announces Closing of $115 Million Initial Public Offering Including Full Exercise of the Over-Allotment Option

October 29, 2021
LAVA Medtech Acquisition Corp. (the “Company”) today announced the closing of its initial public offering of 11,500,000 units at a price of $10.00 per unit, including 1,500,000 units... Learn More

MORE

Team Lumira

Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.

MEET THE TEAM
Image

Philanthropy

Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.

LEARN MORE

  • "Lumira's philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael's ability to accelerate the pace."

    Dr. Arthur Slutsky | Vice-President
    Vice-President of Research at St. Michael's Hospital

  • "Lumira's model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation."

    Barbara Grantham | President & Ceo
    VGH & UBC Hospital Foundation

  • “This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”

    Paul Alofs | President & Ceo
    Princess Margaret Cancer Foundation

Contact Us

Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.

Image

Toronto

141 Adelaide Street
Suite 770
Toronto, ON
Canada, M5H 3L5
416.213.4223

Image

Montreal

Espace CDPQ
3, Place Ville Marie
Bureau 12350, Niveau L
Montreal, QC
Canada, H3B 0E7
514.844.6927

Image

Vancouver

1021 West Hastings Street,
9th floor
Vancouver, BC
Canada, V6E 0C3
604.558.5156

Image

Boston

303 Wyman Street
Suite 300
Waltham, MA,
USA, 02451-1208
781.530.3868